Surgery Partners (SGRY) Q1 2026: Musculoskeletal Joints Up 15%, Robotics and DeNovos Anchor Growth Shift
Surgery Partners’ Q1 2026 results spotlight a decisive pivot toward higher-acuity musculoskeletal (MSK) procedures, with double-digit growth in total joint surgeries and ongoing investments in surgical robotics and de novo ambulatory surgery centers (ASCs). While overall case growth was modest, the business is actively rebalancing its portfolio and cost structure to support margin expansion and long-term deleveraging. Management’s tone is focused on operational discipline and capital deployment, with portfolio optimization and M&A as key levers for the remainder of 2026.
Summary
- MSK and Robotics Drive Mix Shift: Higher-acuity musculoskeletal cases and surgical robots are reshaping the revenue base.
- Portfolio Optimization in Focus: Divestitures and asset rotation are positioned to improve cash conversion and reduce leverage.
- Operational Discipline Signals Margin Upside: Cost controls and physician recruitment underpin margin resilience into the second half.
Business Overview
Surgery Partners is a leading operator of short-stay surgical facilities, primarily focused on ambulatory surgery centers (ASCs) and select surgical hospitals. The company generates revenue through facility fees, ancillary services, and physician partnerships, with a growing emphasis on higher-acuity musculoskeletal (MSK) procedures. Its business is segmented across same-facility operations, de novo development, and M&A-driven expansion, targeting both organic and inorganic growth in a highly fragmented outpatient surgical market.
Performance Analysis
First quarter results reflected a stable but evolving operating environment. Net revenue reached $811 million, with same-facility revenue growth of 4.4% and adjusted EBITDA margin of 12.6%. However, same-facility case growth was a muted 0.6%—below the long-term algorithm—due to weather-driven disruptions in lower-acuity markets, partially offset by robust gains in higher-acuity segments.
Musculoskeletal (MSK) and total joints procedures surged 14.6% year over year, supported by continued investment in surgical robotics (now 73 robots across the portfolio). Physician recruitment remained strong, with 140 new physicians added, particularly in orthopedics, ophthalmology, and GI. Cost discipline was evident as supply and labor expense ratios improved sequentially, partially offsetting new provider taxes and incentive compensation resets.
- MSK Outperformance: Total joints growth outpaced overall case volume, shifting the mix toward higher-margin, complex procedures.
- Cost Efficiency Gains: Supply and wage costs as a percentage of revenue improved, reinforcing the margin narrative despite headwinds from provider taxes.
- De Novo Pipeline Strength: One new ASC opened in Q1, with five more targeted for later in 2026, signaling sustained organic expansion.
Working capital discipline and cash flow conversion improved, with operating cash flow doubling year over year. M&A spend was modest ($4 million), but the pipeline remains active, and portfolio optimization efforts are advancing toward a potential mid-year announcement.
Executive Commentary
"We are encouraged by our start to the year with first quarter performance broadly in line with our internal expectations, reflecting improved stability across the portfolio and initial signs of recovery in areas that were pressured towards the end of 2025."
Eric Evans, Chief Executive Officer
"Supply expense represented approximately 27.2% of net revenue during the quarter, while SWB expense was approximately 30.5% of revenue, both showing modest improvement year over year...We remain focused on disciplined capital allocation and expect to continue to drive gradual deleveraging over time, supported by earnings growth and ongoing portfolio optimization."
Dave Daugherty, Chief Financial Officer
Strategic Positioning
1. Musculoskeletal and Robotics Expansion
The company is doubling down on higher-acuity musculoskeletal (MSK) procedures, with total joints as the flagship growth vector. The deployment of 73 surgical robots is driving clinical adoption and attracting high-value physician partners. This investment enables Surgery Partners to capture complex cases that were historically performed in acute care hospitals, supporting both top-line and margin expansion.
2. De Novo ASC Development
De novo (new build) ASC development is a high-return capital allocation strategy, with nine openings in the trailing twelve months and five more expected later in 2026. These centers are heavily weighted toward MSK, aligning with the broader shift toward outpatient, high-acuity procedures. The pipeline is robust, with a mix of health system partnerships and independent facilities, providing optionality for future consolidation and buy-up opportunities.
3. Portfolio Optimization and Asset Rotation
Management is actively pursuing portfolio optimization, focusing on divesting or restructuring larger surgical hospital assets that fall outside the core short-stay strategy. Advanced discussions are underway for at least one key market, targeting mid-2026 for a potential announcement. The goal is to reduce leverage, improve free cash flow conversion, and simplify the business model for sustained growth.
4. Margin Management and Cost Discipline
Cost control remains a central theme, with sequential improvements in labor and supply costs as a percentage of revenue. Management is proactively addressing headwinds from provider taxes and payer mix, leveraging scale and operational discipline to protect margins. The SWB (salaries, wages, and benefits) line is expected to normalize in coming quarters as incentive compensation is reinstated, but overall margin trajectory is positive.
5. Physician Recruitment and Commercial Mix
Physician recruitment is both a growth and risk mitigation lever, with 140 new physicians added in Q1 and a continued focus on high-acuity specialties. Commercial payer mix, while under modest pressure, is stabilizing, and management is executing targeted actions to recover and grow market share. The company is less exposed to exchange populations and ER-driven volatility, supporting revenue predictability.
Key Considerations
This quarter’s results highlight a deliberate rebalancing toward higher-acuity, technology-enabled procedures, with operational discipline and capital deployment as key levers for long-term value creation. Investors should monitor the following:
Key Considerations:
- MSK and Robotics Scale-Up: Sustained double-digit growth in total joints and ongoing robotics investment are reshaping the revenue and margin profile.
- Portfolio Optimization Timeline: Asset divestitures in non-core surgical hospital markets are expected to unlock cash flow and reduce leverage, with a key transaction targeted for mid-2026.
- Cost Structure Resilience: Improvement in supply and labor costs signals margin durability, but provider tax headwinds and incentive compensation resets warrant ongoing attention.
- Organic and Inorganic Growth Balance: De novo ASC openings and a healthy M&A pipeline provide upside optionality, with M&A not included in 2026 guidance.
- Physician Pipeline and Commercial Share: Recruitment trends and payer mix stabilization are critical for sustaining growth and offsetting demographic headwinds.
Risks
Provider tax increases and payer mix shifts remain ongoing margin risks, particularly as commercial share faces demographic and competitive pressures. The timing and execution of portfolio optimization and M&A are inherently uncertain and could impact deleveraging goals. Regulatory shifts (e.g., prior authorization, CMS demo models) may introduce administrative complexity and reimbursement volatility, though current management commentary frames these as net tailwinds for the ASC model.
Forward Outlook
For Q2 2026, Surgery Partners guided to:
- Revenue representing 24 to 24.5% of the annual target
- Adjusted EBITDA at 23 to 23.5% of the annual target
For full-year 2026, management reiterated guidance:
- Revenue of $3.35 to $3.45 billion
- Adjusted EBITDA of at least $530 million
Management highlighted several factors that will drive results:
- Seasonal normalization of case mix and rate in Q2
- Back-half weighting of earnings from portfolio optimization and cost actions
Takeaways
Surgery Partners is methodically transitioning its business toward higher-acuity, technology-enabled procedures, with MSK and robotics at the core. Margin management and operational discipline are offsetting payer and tax headwinds. Portfolio optimization and de novo expansion provide optionality for deleveraging and growth acceleration.
- MSK and Robotics Outperformance: High-acuity case growth is driving mix shift and margin expansion, with technology as an enabler.
- Operational and Capital Discipline: Cost controls and cash flow focus are supporting gradual deleveraging and margin resilience.
- Portfolio Actions as Catalysts: Asset rotation and M&A are positioned to unlock value and reset the growth trajectory into 2027.
Conclusion
Surgery Partners’ Q1 2026 results underscore a disciplined, strategic pivot toward higher-value, technology-enabled outpatient care, with MSK and robotics anchoring the next phase of growth. While case growth was modest, the company’s operational rigor, portfolio optimization, and recruitment engine position it for margin expansion and sustainable deleveraging through 2026 and beyond.
Industry Read-Through
The continued migration of high-acuity procedures to outpatient ASCs, enabled by robotics and regulatory support (e.g., removal of the inpatient-only list), is accelerating across the healthcare sector. Surgery Partners’ experience suggests that technology adoption, physician alignment, and payer strategy are critical for capturing this migration. Other ASC operators and hospital systems must invest in robotics and de novo development to remain competitive, while traditional acute care hospitals risk ceding profitable case volume to more agile, cost-efficient platforms. The industry should expect further consolidation, with disciplined capital deployment and portfolio optimization as key differentiators.